Sagimet Biosciences (SGMT) Other Non-Current Liabilities (2022 - 2023)
Sagimet Biosciences' (SGMT) quarterly Other Non-Current Liabilities came in at $1000.0 in Q3 2023, down 80.0% quarter-over-quarter from $5000.0 in Q2 2023.
Sagimet Biosciences (SGMT) Other Non-Current Liabilities (2022 - 2023) Analysis & Trends
Sagimet Biosciences' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1000.0 for Q3 2023.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $1000.0 in Q3 2023; TTM through Sep 2023 was $1000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $4000.0, changed N/A from the prior year.
- Other Non-Current Liabilities fell to $1000.0 in Q3 2023 per SGMT's latest filing, from $5000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $5000.0 in Q2 2023 and bottomed at $1000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Sagimet Biosciences | 227.27 Mn | 227.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Dec 31, 2022 | 4,000.00 |